 |
|
|
| |
New HCV Protease: Preclinical Characteristics and Microdosing Pharmacokinetics in Healthy Volunteers Support a Low-Dose, Once-Daily Dosing Regimen of the HCV NS3/4a Protease Inhibitor ITMN-8187
|
| |
| |
Ravi Rajagopalan
InterMune Inc., Brisbane, CA
Reported by Jules Levin
The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy
Boston, MA June 23-24, 2010
|
| |
|
|
|
|
|
